<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Function of Axl receptor tyrosine kinase in non-small cell lung cancer (Review)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Guoan</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Cancer Pathology Research Institute</orgName>
								<orgName type="institution" key="instit2">Jining Medical University</orgName>
								<address>
									<postCode>272067</postCode>
									<settlement>Jining</settlement>
									<region>Shandong</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MENG</roleName><surname>Wang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Shandong Jining First People&apos;s Hospital</orgName>
								<address>
									<postCode>272111</postCode>
									<settlement>Jining</settlement>
									<region>Shandong</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hongli</forename><surname>Zhao</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Gastroenterology</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Shandong Control Center for Digestive Diseases</orgName>
								<address>
									<postCode>272033</postCode>
									<settlement>Jining</settlement>
									<region>Shandong</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Wen</forename><surname>Cui</surname></persName>
							<email>cuiwenmd@126.com</email>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">Cancer Pathology Research Institute</orgName>
								<orgName type="institution" key="instit2">Jining Medical University</orgName>
								<address>
									<postCode>272067</postCode>
									<settlement>Jining</settlement>
									<region>Shandong</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Cancer Pathology Research Institute</orgName>
								<orgName type="institution" key="instit2">Jining Medical University</orgName>
								<address>
									<addrLine>16 Beihu Road</addrLine>
									<postCode>272067</postCode>
									<settlement>Jining</settlement>
									<region>Shandong</region>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Function of Axl receptor tyrosine kinase in non-small cell lung cancer (Review)</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">37B50B9D87D9B01940C662C8CDB5ED72</idno>
					<idno type="DOI">10.3892/ol.2017.7694</idno>
					<note type="submission">Received May 5, 2016; Accepted November 7, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>non-small cell lung cancer</term>
					<term>Axl receptor tyrosine kinase</term>
					<term>drug resistance</term>
					<term>epithelial-mesenchymal transition</term>
					<term>invasion</term>
					<term>metastasis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Axl receptor tyrosine kinase (hereafter Axl) is a member of the tyrosine-protein kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein kinase Mer family of receptor tyrosine kinases, possessing multiple different functions in normal cells.</s><s>Axl is overexpressed and activated in numerous different human cancer types, triggering several signaling pathways and enhancing tumor progression.</s><s>The present review assesses previous studies on the function of Axl in non-small cell lung cancer (NSCLC).</s><s>Axl is overexpressed in the tumor tissues of a number of patients with NSCLC and is associated with poorer clinical outcomes; it promotes NSCLC tumor growth, invasion/metastasis, drug resistance and the epithelial-mesenchymal transition, thus providing a survival advantage to tumor cells.</s><s>Therefore, Axl may be a promising target in NSCLC treatment.</s><s>Contents 1. Introduction 2. Axl activation and signaling 3. Function of Axl in NSCLC 4. Conclusion</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Axl receptor tyrosine kinase (hereafter Axl) is a member of the tyrosine-protein kinase receptor Tyro3 (hereafter Tyro3), Axl and proto-oncogene tyrosine-protein kinase Mer (hereafter Mer) (TAM) family of receptor tyrosine kinases (RTKs) <ref type="bibr" target="#b0">(1)</ref>.</s><s>The TAM family is distinguished from other RTKs by a conserved sequence, KW(I/L)A(I/L)ES, within the kinase domain and two immunoglobulin (Ig)-like domains plus two fibronectin type III domains, which comprise nearly the entire ectodomain of each family member <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2)</ref>.</s><s>In adult tissues, Tyro3, Axl and Mer are widely distributed <ref type="bibr" target="#b0">(1)</ref>, and have notable functions in tissue repair, clearance of apoptotic material and immune regulation <ref type="bibr" target="#b0">(1,</ref><ref type="bibr">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref>.</s><s>TAM receptors were initially considered to be orphan receptors <ref type="bibr" target="#b5">(6)</ref>; however, it has since been revealed that there are diverse ligands for this family of receptors <ref type="bibr" target="#b5">(6)</ref><ref type="bibr" target="#b7">(7)</ref><ref type="bibr" target="#b8">(8)</ref><ref type="bibr" target="#b9">(9)</ref><ref type="bibr" target="#b10">(10)</ref>.</s><s>Growth arrest-specific 6 (Gas6) and protein S were identified to be ligands for TAMs in the 1990s <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b7">7)</ref>.</s><s>These proteins are members of the vitamin K-dependent protein family, and demonstrated significant homology with each other <ref type="bibr" target="#b8">(8)</ref>.</s><s>Gas6 binds to all three TAM RTKs (Axl&gt;Tyro3&gt;Mer), whereas protein S interacts with Mer and Tyro3, but not Axl.</s><s>Previously, tubby, tubby-like protein 1 (Tulp-1) and galectin-3 have been revealed to be ligands for TAM receptors, and Tulp-1 binds to all three RTKs with differing levels of affinity, whereas tubby only binds to Mer <ref type="bibr" target="#b9">(9,</ref><ref type="bibr" target="#b10">10)</ref>.</s></p><p><s>The name Axl is derived from the Greek word anexelekto, which means 'uncontrolled'.</s><s>The human Axl gene is located on chromosome 19q13.2</s><s>and has 20 exons <ref type="bibr" target="#b11">(11)</ref>.</s><s>It was originally identified as a transforming gene in the cells of patients with chronic myelogenous leukemia <ref type="bibr" target="#b12">(12)</ref> and had transforming potential when overexpressed in NIH/3T3 fibroblasts <ref type="bibr" target="#b13">(13,</ref><ref type="bibr" target="#b14">14)</ref>.</s><s>As with other RTKs, Axl is composed of an extracellular domain, a transmembrane domain and an intracellular domain.</s><s>A soluble Axl has also been reported <ref type="bibr" target="#b15">(15)</ref>, which may possess a diagnostic value for early-stage hepatocellular carcinoma <ref type="bibr" target="#b16">(16)</ref>.</s><s>Axl is ubiquitously expressed in human tissues <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b17">17)</ref>, with notable levels identified in the kidney <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b18">18)</ref>, brain <ref type="bibr" target="#b19">(19)</ref>, heart <ref type="bibr" target="#b0">(1)</ref>, testis <ref type="bibr" target="#b0">(1)</ref>, skeletal muscle <ref type="bibr" target="#b0">(1)</ref>, liver <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b20">20)</ref>, endothelial cells <ref type="bibr" target="#b21">(21,</ref><ref type="bibr" target="#b22">22)</ref>, monocytes/macrophages <ref type="bibr" target="#b23">(23)</ref> and platelets <ref type="bibr" target="#b24">(24)</ref>.</s><s>This wide expression pattern of Axl indicates that this protein exerts a notable function in normal cell function, including cell survival, proliferation, migration and adhesion <ref type="bibr" target="#b17">(17)</ref>.</s><s>However, usually, more than one TAM receptor is expressed in a given cell type simultaneously that may be activated by one common ligand; for example, all three TAM members may be activated by Gas6 <ref type="bibr" target="#b25">(25)</ref>, thus making it difficult to elucidate the function of Axl on its own in one cell type.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Axl activation and signaling</head><p><s>Axl is activated by Gas6.</s><s>The activation of RTKs involves ligand binding to the extracellular domain, which induces receptor dimerization and subsequent trans-autophosphorylation of the tyrosine residues within the cytoplasmic domain <ref type="bibr" target="#b1">(2)</ref>.</s><s>Axl is activated by the binding of its ligand Gas6, which was identified as the ligand for Axl in 1995 by two separate studies <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b7">7)</ref>.</s><s>Prior to that, the Gas6 gene was first identified as one of several genes to be upregulated in NIH/3T3 fibroblasts under serum starvation-induced growth arrest <ref type="bibr" target="#b26">(26)</ref>.</s><s>Gas6 was later revealed to be a common ligand for Axl, Tyro3 and Mer, with Axl possessing the highest affinity for Gas6 (3).</s><s>Gas6 is widely expressed and has been identified in the lung, heart, kidney, intestine, endothelial cells, bone marrow, vascular smooth muscle cells and monocytes and at low levels in the liver and human blood plasma <ref type="bibr" target="#b27">(27)</ref>.</s><s>It has cell-type-specific functions, including platelet aggregation and hematopoiesis, proliferation, survival and phagocytosis.</s></p><p><s>Gas6 possesses an N-terminal region containing a modified γ-carboxyglutamic acid (Gla) residue, which has the ability to interact with negatively charged membrane phospholipids to mediate the binding of Gas6 to apoptotic cells.</s><s>The Gla domain is followed by a loop region, four epidermal growth factor (EGF)-like repeats and a C-terminal sex-hormone-binding globulin (SHBG)-like structure that is composed of two globular laminin G-like domains <ref type="bibr" target="#b28">(28)</ref>.</s><s>The SHBG domain binds directly to the Ig domains of Axl, which results in the formation of a Gas6/Axl complex with a 1:1 ratio <ref type="bibr" target="#b29">(29)</ref>.</s><s>The lateral diffusion of these complexes would then result in the formation of a minimal 2:2 Gas6/Axl signaling complex, which induces activation of Axl <ref type="bibr" target="#b29">(29)</ref>.</s><s>Additionally, the γ-carboxylation of Gas6 and anionic phospholipids, including the externalized phosphatidylserine on apoptotic cells and enveloped viruses, possesses vital functions for the activation of Axl <ref type="bibr">(3,</ref><ref type="bibr" target="#b30">30,</ref><ref type="bibr" target="#b31">31)</ref>.</s></p><p><s>Atypical activation of Axl.</s><s>In addition to conventional activation, atypical activation of Axl has been reported, including activation by crosstalk between receptors (1).</s><s>Meyer et al <ref type="bibr" target="#b32">(32)</ref> revealed that EGF receptor (EGFR) activation associated with Axl and EGF stimulation may activate Axl through EGFR in triple-negative breast cancer cells.</s><s>In non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) <ref type="bibr" target="#b33">(33,</ref><ref type="bibr" target="#b34">34)</ref> and esophageal squamous cell carcinomas (ESCC) cells <ref type="bibr" target="#b34">(34)</ref>, this physical association between Axl and EGFR was also observed.</s><s>This interaction has the potential to activate EGFR <ref type="bibr" target="#b33">(33,</ref><ref type="bibr" target="#b34">34)</ref> and Axl <ref type="bibr" target="#b32">(32,</ref><ref type="bibr" target="#b33">33)</ref>.</s><s>The ability of Axl to form complexes with other RTKs may make certain cancer types resistant to tyrosine kinase inhibitors (TKIs), as will be discussed further in the present review.</s></p><p><s>Three tyrosine residues, Y-779, Y-821 and Y-866, within the C-terminal domain of Axl have been proposed as potential autophosphorylation sites and putative docking sites for a variety of signaling proteins (1), including the p85a and p85b subunits of phosphatidylinositol 3-kinase (PI3K) <ref type="bibr" target="#b35">(35,</ref><ref type="bibr" target="#b36">36)</ref>, growth factor receptor-bound protein 2 <ref type="bibr" target="#b25">(25,</ref><ref type="bibr" target="#b26">26)</ref>, phospholipase Cγ (PLCγ) <ref type="bibr" target="#b36">(36)</ref>, c-src and lck (36) (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Additionally, the engulfment and cell motility (Elmo) scaffold protein has been reported to directly interact with Axl, and serves vital functions in Axl-induced breast cancer invasion <ref type="bibr" target="#b37">(37)</ref>.</s><s>Notably, mutation of the three tyrosine residues did not abrogate the Axl-Elmo2 association, indicating that other docking sites may exist <ref type="bibr" target="#b37">(37)</ref>.</s></p><p><s>Activation of Axl regulates a number of signal transduction pathways, depending on the cell types in question, primarily PI3K/protein kinase B (Akt) and mitogen-activated protein kinase (MEK)/extracellular-signal-regulated kinase (ERK), nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 (STAT3) <ref type="bibr" target="#b17">(17,</ref><ref type="bibr" target="#b38">38,</ref><ref type="bibr" target="#b39">39)</ref> [references <ref type="bibr" target="#b0">(1,</ref><ref type="bibr">3,</ref><ref type="bibr" target="#b17">17,</ref><ref type="bibr" target="#b40">40)</ref> contain further information on Axl signaling].</s><s>The activation of Staining intensity was graded as 0 (no staining), 1 (weak), <ref type="bibr" target="#b52">(52)</ref> significantly associated with worse 2 (moderate), or 3 (strong), and percentage of positive cells clinicopathological features (lymph was graded as 0 (negative), 1 (&lt;10%), 2 (11-50%), node metastasis) and prognosis (overall 3 (51-80%), or 4 (&gt;80%).</s><s>The final IHC score was obtained survival and disease-free survival).</s><s>by multiplication of the two grading results.</s><s>A score &gt;7 was considered to be Axl IHC high.</s><s>these pathways elicits different responses in different cells, including cell proliferation, migration or survival (3,17) (Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Function of Axl in NSCLC</head><p><s>Axl is overexpressed in a subset of NSCLC, and is associated with poorer clinical outcomes.</s><s>The expression of Axl and Gas6 in normal lung cells is not well documented.</s><s>Studies aimed at detecting Axl expression in lung cancer cells demonstrated that Axl is not expressed in normal lung alveolar cells or the bronchial epithelium adjacent to a tumor <ref type="bibr" target="#b41">(41,</ref><ref type="bibr" target="#b42">42)</ref>.</s><s>Axl is expressed in lung airway macrophages, but not interstitial macrophages and other lung leukocytes under homeostatic conditions and is constitutively ligated to Gas6 <ref type="bibr" target="#b43">(43)</ref>.</s><s>Axl was believed to serve notable functions in mediating immune homeostasis through the clearance of apoptotic cells during inflammation <ref type="bibr" target="#b43">(43)</ref> and promoting an antiviral response through maintaining the appropriate production of type I interferon <ref type="bibr" target="#b44">(44)</ref>.</s><s>Axl and Gas6 are also expressed in the blood endothelial cells of lung <ref type="bibr" target="#b45">(45)</ref>, in which they maintaining the integrity of the vasculature and vascular remodeling under pathological conditions <ref type="bibr" target="#b27">(27)</ref>.</s></p><p><s>Axl is expressed in NSCLC, with expression rates varying from ~33.0 to ~93.2% detected by different groups (Table <ref type="table">I</ref>).</s><s>This inconsistency may be caused by different Axl antibodies used, and different evaluation methods.</s><s>The varying clinicopathological characteristics of patients with NSCLC studied may also contribute to this inconsistence.</s><s>These studies suggest a number of patients with NSCLC express Axl, and it may be associated with a poorer prognosis.</s><s>Consistently, patients with NSCLC that exhibit high Axl mRNA expression had a shorter disease-free survival time than patients exhibiting low Axl mRNA expression <ref type="bibr" target="#b46">(46)</ref>.</s></p><p><s>Axl and tumor growth in NSCLC.</s><s>Similar to other RTKs, Axl overexpression may provide survival and growth advantages to tumor cells <ref type="bibr">(3)</ref>.</s><s>In NSCLC cell lines, the small interfering RNA (siRNA)-mediated downregulation of Axl results in decreased cell growth in vitro and in xenograft mouse models <ref type="bibr" target="#b41">(41,</ref><ref type="bibr" target="#b47">47)</ref>, in addition to the suppression of Akt and ERK activation <ref type="bibr" target="#b34">(34)</ref>.</s><s>Similarly, the proliferation of H226 cells, which express moderate levels of Axl, may be suppressed by the anti-Axl monoclonal antibody MAb173 or the specific Axl inhibitor R428 <ref type="bibr" target="#b33">(33)</ref>.</s><s>These studies indicate that Axl is involved in maintaining the proliferation of NSCLC cells.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Axl and the epithelial-mesenchymal transition (EMT) in NSCLC.</head><p><s>EMT is a process by which epithelial cells lose their cell polarity and cell-cell adhesion, and gain mesenchymal cell-like migratory and invasive properties <ref type="bibr" target="#b48">(48)</ref>.</s><s>Axl is recognized as having vital functions in NSCLC EMT.</s><s>Firstly, Axl a marker for the mesenchymal phenotype in NSCLC.</s><s>From the RNA-sequencing data of 643 cancer cell lines, including NSCLC, Axl expression was markedly associated with a mesenchymal phenotype <ref type="bibr" target="#b49">(49)</ref>.</s><s>It was further revealed that in 45 NSCLC cell lines, higher Axl protein expression tends to be associated a higher protein expression of vimentin, a mesenchymal <ref type="bibr" target="#b49">(49)</ref>.</s><s>Similarly, Axl expression was higher in NSCLC mesenchymal cancer cells than in epithelial cancer cells, based on the mRNA expression profile of 54 NSCLC cell lines and the protein expression data of 49 patients with NSCLC <ref type="bibr" target="#b50">(50)</ref>.</s></p><p><s>Furthermore, in the transforming growth factor β-induced EMT model, Axl is upregulated, similar to vimentin <ref type="bibr" target="#b49">(49)</ref>.</s><s>In addition, Axl aids the maintenance of the EMT state in NSCLC cells.</s><s>A549 and H460 are mesenchymal NSCLC cells <ref type="bibr" target="#b50">(50)</ref>; in these cell lines, Axl downregulation results in the increased expression of E-cadherin and decreased expression of vimentin and N-cadherin, which are features of the reverse of EMT <ref type="bibr" target="#b47">(47)</ref>.</s></p><p><s>Axl and NSCLC invasion and migration.</s><s>Patients with cancer that have solid tumors primarily succumb to mortality due to metastatic lesions rather than from the primary tumors <ref type="bibr" target="#b51">(51)</ref>.</s><s>Axl has been implicated in metastasis in multiple tumor types <ref type="bibr">(3)</ref>.</s><s>In patients with NSCLC, Axl expression is associated with lymph node metastasis <ref type="bibr" target="#b52">(52)</ref><ref type="bibr" target="#b53">(53)</ref><ref type="bibr" target="#b54">(54)</ref>.</s><s>Cisplatin-and gefitinib-resistant HCC4006 cells express high levels of Axl, and siRNA-mediated Axl downregulation suppressed the migratory capacity of these cells <ref type="bibr" target="#b55">(55)</ref>.</s><s>Lay et al <ref type="bibr" target="#b56">(56)</ref> established a series of cell lines with different invasive abilities by the selection of increasingly invasive cancer cell populations from a cell line of human lung adenocarcinoma (CL1-0) using a Transwell invasion chamber assay.</s><s>It was revealed that Axl expression was highly associated with the migratory ability of these cell lines.</s><s>NF-κB signaling was responsible for Axl-enhanced migration, with its suppression blunting Axl-induced migration.</s><s>Huang et al <ref type="bibr" target="#b57">(57)</ref> additionally reported that Axl mediates H 2 O 2 -induced migration by activating PI3K/Akt/Ras-related C3 botulinum toxin substrate 1 signaling.</s><s>Furthermore, the first Ig-like domain and the intracellular domain were vital for the function of Axl in these two models.</s><s>These studies indicated that Axl may not only activate migration-promoting signals itself, but additionally mediate the effect of other molecules to increase migration.</s><s>Mechanistically, Axl increases the expression of matrix metalloproteinase-9 (MMP9) and MMP2, which promote tissue remodeling and cancer invasion <ref type="bibr" target="#b58">(58)</ref><ref type="bibr" target="#b59">(59)</ref><ref type="bibr" target="#b60">(60)</ref><ref type="bibr" target="#b61">(61)</ref>.</s><s>Additionally, as discussed above, Axl promotes the EMT of cancer cells <ref type="bibr" target="#b62">(62,</ref><ref type="bibr" target="#b63">63)</ref>, a process associated with migratory and invasive properties <ref type="bibr" target="#b48">(48)</ref>.</s><s>Axl has also been associated with invasion through the modification of the cytoskeleton regulator Rac <ref type="bibr" target="#b37">(37,</ref><ref type="bibr" target="#b57">57,</ref><ref type="bibr" target="#b64">64)</ref>, leading to cytoskeletal reorganization and increased migration and invasion.</s></p><p><s>Axl and cancer drug resistance in NSCLC.</s><s>Drug resistance is the main reason for the failure of cancer treatments.</s><s>Axl serves a notable function in the drug resistance of a number of different cancer types <ref type="bibr" target="#b34">(34,</ref><ref type="bibr" target="#b65">(65)</ref><ref type="bibr" target="#b66">(66)</ref><ref type="bibr" target="#b67">(67)</ref>; its function in NSCLC drug resistance has been studied intensively <ref type="bibr" target="#b68">(68)</ref>.</s><s>Evidence is primarily derived from in vitro cell line studies (Table <ref type="table">II</ref>), with limited data from mouse models <ref type="bibr" target="#b33">(33,</ref><ref type="bibr" target="#b69">69)</ref> and the tumor tissues of patients with cancer (69,70) (Table <ref type="table" target="#tab_1">III</ref>).</s><s>Thus, these results may require further confirmation, particularly in human tumors in vivo.</s></p><p><s>The majority of cell line-based studies use drug-resistant cells, obtained by the long-term treatment of cancer cells with increasing doses of drugs, and such studies have revealed that Axl is upregulated in drug-resistant cancer cells (Table <ref type="table">II</ref>).</s><s>One study additionally revealed that suppression of Axl with genomic or pharmaceutical methods may restore the sensitivity of cancer cells to drugs, further informing on the function of Axl in these drug-resistant models <ref type="bibr" target="#b69">(69)</ref>.</s><s>Other studies downregulated Axl expression in Axl-overexpressed NSCLC cancer Table <ref type="table">II</ref>.</s><s>Cell line-based evidence on Axl upregulation being an independent mechanism of non-small cell lung carcinoma drug resistance.</s><s><ref type="figure">--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</ref> cells, including A549 and H462, to survey the change of the half maximal inhibitory concentration of cancer cells to drugs, and it was observed that the silencing of Axl enhanced the sensitivity of cancer cells to drugs, including several chemotherapeutic drugs and erlotinib <ref type="bibr" target="#b41">(41,</ref><ref type="bibr" target="#b47">47)</ref>.</s><s>Zhang et al <ref type="bibr" target="#b69">(69)</ref> used a combination of strategies, including mouse models and matched NSCLC tumor tissues (tissues from the same patient prior to treatment and following the development of drug resistance), providing convincing evidence supporting the involvement of Axl in the mechanisms underlying NSCLC EGFR TKI resistance, and that targeting this molecule may restore the sensitivity of resistant cells.</s><s>Similarly, Brand et al <ref type="bibr" target="#b33">(33)</ref> used several differing strategies, including the ectopic overexpression of Axl, siRNA-mediated downregulation of Axl and mouse models, to demonstrate that Axl serves a notable function in NSCLC resistance to cetuximab, a chimeric monoclonal antibody targeting EGFR.</s><s>In addition to the work of Zhang et al <ref type="bibr" target="#b69">(69)</ref>, Ji et al <ref type="bibr" target="#b70">(70)</ref> provides further evidence using the tumor tissue of patients with NSCLC demonstrating that Axl upregulation is an independent mechanism of NSCLC resistance to EGFR-TKI (Table <ref type="table" target="#tab_1">III</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Main results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Models used</head><p><s>A detailed mechanism for Axl-mediated drug resistance is yet to be elucidated.</s><s>However, a number of studies have provided notable information.</s><s>As previously discussed, the overexpression of Axl is linked to EMT status, which was associated with drug resistance <ref type="bibr" target="#b71">(71,</ref><ref type="bibr" target="#b72">72)</ref>.</s><s>Additionally, Axl impedes therapeutically induced apoptosis by exerting anti-apoptotic effects by modulating the expression or activation of apoptosis regulators, including B-cell lymphoma extra large, survivin <ref type="bibr" target="#b41">(41)</ref>, B-cell lymphoma-2 (Bcl-2) associated agonist of cell death (73), Bh3 interacting-domain death agonist <ref type="bibr" target="#b74">(74)</ref> and Bcl-2 <ref type="bibr" target="#b75">(75)</ref>.</s><s>Additionally, a number of previous studies have suggested that the ability of Axl to form complexes with other RTKs may be one key aspect of this function.</s><s>Cetuximab-resistant NSCLC cell line H226 cells exhibited upregulation of Axl signaling, which was further elucidated to form a physical complex with EGFR <ref type="bibr" target="#b33">(33)</ref>.</s><s>Furthermore, treatment with EGF or tumor necrosis factor resulted in H226 cells resistant to cetuximab, with the formation of a physical complex between Axl and EGFR, similar to that in resistant cells.</s><s>This indicates that the Axl-EGFR complex serves a role in eliciting a drug-resistant phenotype of cancer cells.</s><s>These studies further demonstrated that Axl and EGFR were involved in maintaining the growth of these resistant cells.</s><s>Additionally, silencing the expression of either Axl or EGFR with siRNA decreased the growth of these cells.</s><s>The Axl-EGFR complex was also observed in other drug resistant cancer models.</s><s>For example, as mentioned above, HNSCC and ESCC cells induced to be resistant to PI3K inhibitor BYL719 additionally displayed this Axl-EGFR complex <ref type="bibr" target="#b34">(34)</ref>.</s><s>In sensitive parental cells, EGFR activated the PI3K/Akt pathway, which maintained mechanistic target of rapamycin (mTOR) activity <ref type="bibr" target="#b76">(76)</ref>.</s><s>In resistant cells, the Axl-EGFR complex activated PLCγ-protein kinase C (PKC) signaling, which in turn activated mTOR <ref type="bibr" target="#b76">(76)</ref>.</s><s>Thus, tumor cells became less dependent on PI3K/Akt signaling and resistant to PI3K inhibitor BYL719.</s><s>Combining BYL719 and R428 may reverse the resistant phenotype.</s><s>This complex additionally formed in breast cancer cells, and Axl in this complex amplified and diversified EGFR signaling <ref type="bibr" target="#b32">(32)</ref>.</s><s>Thus, it may be that this complex increased the resistance of cancer cells to EGFR inhibitors and that the suppression of Axl may enhance the efficacy of EGFR inhibitors.</s><s>Further studies revealed that the suppression of Axl activation with R428 significantly increased the killing ability of erlotinib <ref type="bibr" target="#b32">(32)</ref>.</s><s>Furthermore, Wu et al <ref type="bibr" target="#b54">(54)</ref> revealed that Axl and EGFR are co-expressed in a subset of NSCLC tumor tissues.</s><s>This may allow this complex to form readily, promoting drug resistance.</s><s>Other receptors, including human epidermal growth factor receptor 2 (HER2), HER3, MET proto-oncogene and platelet-derived growth factor receptor-β have been reported to be associated with Axl <ref type="bibr" target="#b32">(32)</ref>.</s><s>This association of Axl with other receptors may have implications for targeted therapies, as these complexes may change the response of RTKs to TKIs, or make cancer cells less dependent on the signaling pathways that were targeted <ref type="bibr" target="#b34">(34)</ref>, which may result in cancer cells resistant to TKIs.</s></p><p><s>There are additional reports indicating a minimal function of Axl in the resistance of NSCLCs to TKIs.</s><s>For example, the suppression of Axl with siRNA or chemical inhibitors in erlotinib-resistant H358 (77) and HCC827 (49) cells, which demonstrated an increased expression of Axl, could not restore the sensitivity of the cells to drug treatment.</s><s>NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; Gas6, growth arrest-specific 6.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Conclusion</head><p><s>Axl is a promising therapeutic target, considering that it serves notable functions in NSCLC tumor growth, EMT, invasion and drug resistance.</s><s>A number of Axl inhibitors have been developed and a number are in clinical trials, including foretinib (XL880, GSK1363089), cabozantinib, crizotinib, ASLAN002 and BGB324 (R428) <ref type="bibr">(3,</ref><ref type="bibr" target="#b78">(78)</ref><ref type="bibr" target="#b79">(79)</ref><ref type="bibr" target="#b80">(80)</ref><ref type="bibr" target="#b81">(81)</ref>.</s><s>It is important to note that although a wide range of Axl kinase inhibitors have been described, a majority of them are nonspecific multi-kinase inhibitors.</s><s>BGB324 (R428) was the first selective Axl inhibitor to be developed <ref type="bibr" target="#b82">(82)</ref>.</s><s>Oral treatment with BGB324 (R428) in mouse xenograft models revealed that it reduced breast cancer metastasis and prolonged survival.</s><s>It entered phase 1 clinical trials in 2013 <ref type="bibr" target="#b83">(83)</ref>.</s><s>At present, clinical trials including patients with melanoma, NSCLC and acute myeloid leukemia are ongoing to determine the safety and efficiency of BGB324 (https://clinicaltrials.gov/ct2/results?cond=&amp;term=BGB324&amp;cntry1=&amp;state1= &amp;Search=Search).</s><s>The identification of appropriate biomarkers for the selection of patients is another key issue for the development of Axl-targeted therapies.</s><s>Immunohistochemistry appears to be the most feasible strategy for identifying appropriate biomarkers, with other strategies including the detection of Axl expression in vivo by single-photon emission computed tomography imaging using a 125 I-labled Axl antibody <ref type="bibr" target="#b84">(84)</ref>.</s><s>With the development of AXL inhibitors, and an increase in the understanding of the underlying molecular mechanisms responsible for NSCLC, patients who are suitable for AXL-targeted therapies could be screened and treated with this form of therapy.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Schematic representation of the Axl signaling pathway.</s><s>Activation of Axl by Gas6 binding results in the autophosphorylation of several tyrosine residues in the intracellular domain, including Y-779, Y-821 and Y-866, which provide docking sites for signaling proteins and consequently result in the activation of the PI3K/Akt pathway, RAS/ERK pathway, STAT3 pathway, NF-κB pathway, PLCγ-Ca 2+ /PKC pathway and Elmo2-Rac pathway, promoting tumor proliferation, survival and migration.</s><s>The question mark represents the tyrosine sites responsible for JAK and Elmo2 activation remain unknown.</s><s>Gas6, growth arrest-specific 6; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; ERK, extracellular signal-regulated kinase; STAT3, signal transducer and activator of transcription 3; NF-κB, nuclear factor-κB; PLCγ, phosphoinositide phospholipase Cγ; PKC, protein kinase C; Elmo2, engulfment and cell motility 2; JAK, Janus kinase.</s></p></div></figDesc><graphic coords="2,95.27,57.64,404.74,175.61" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>cells' resistance to drugs in enhanced sensitivity to drugs (Refs.)Choi</s><s>et al,</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table III .</head><label>III</label><figDesc><div><p><s>Patient tumor tissue-based evidence to demonstrate that Axl upregulation is an independent mechanism of NSCLC drug resistance.</s></p></div></figDesc><table><row><cell>Author, year</cell><cell>Tumor tissues description</cell><cell>Patients, n</cell><cell>Main results</cell><cell>(Refs.)</cell></row><row><cell cols="2">Zhang et al, 2012 Matched EGFR mutant NSCLC specimens</cell><cell>35</cell><cell>Compared with the treatment-native</cell><cell>(69)</cell></row><row><cell></cell><cell>obtained prior to treatment with EGFR TKIs</cell><cell></cell><cell>tumor tissues, a higher expression</cell><cell></cell></row><row><cell></cell><cell>erlotinib or gefitinib and following the</cell><cell></cell><cell>level of Axl and Gas6 were detected in</cell><cell></cell></row><row><cell></cell><cell>development of resistance to these</cell><cell></cell><cell>7/35 (20%) and 7/28 (25%) of</cell><cell></cell></row><row><cell></cell><cell>compounds.</cell><cell></cell><cell>TKI-resistant tissues, respectively.</cell><cell></cell></row><row><cell>Ji et al, 2013</cell><cell>Matched EGFR mutant NSCLC specimens</cell><cell>26</cell><cell cols="2">Increased Axl expression was observed (70)</cell></row><row><cell></cell><cell>obtained prior to treatment with EGFR TKIs</cell><cell></cell><cell>in 5/26 (19.2%) of patients with</cell><cell></cell></row><row><cell></cell><cell>erlotinib or gefitinib and following the</cell><cell></cell><cell>TKI-resistant NSCLC.</cell><cell></cell></row><row><cell></cell><cell>development of resistance to these compounds.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The present review was supported by the Project of Shandong Province Higher Educational Science and Technology Program (grant no.</s><s>J13LK14).</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Linger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Earp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Cancer Res</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="35" to="83" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cell signaling by receptor tyrosine kinases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lemmon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schlessinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="1117" to="1134" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Deryckere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Earp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="769" to="785" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">TAM receptor signaling in immune homeostasis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Rothlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Carrera-Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bosurgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghosh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="355" to="391" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Immunobiology of the TAM receptors</title>
		<author>
			<persName><forename type="first">G</forename><surname>Lemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Rothlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="327" to="336" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">The anticoagulation factor protein S and its relative</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Stitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Conn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Radziejewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mattsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Gies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Jones</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Gas6, are ligands for the Tyro</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Axl family of receptor tyrosine kinases</title>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="661" to="670" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Varnum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Bartley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Fridell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Trail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Clogston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Toso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="623" to="626" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade</title>
		<author>
			<persName><forename type="first">G</forename><surname>Manfioletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brancolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Avanzi</forename></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="4976" to="4985" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Galectin-3 is a new MerTK-specific eat-me signal</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Caberoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alvarado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Bigcas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">227</biblScope>
			<biblScope unit="page" from="401" to="407" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Caberoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3898" to="3910" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Targeting Axl and Mer kinases in cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Warner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vankayalapati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Bearss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1763" to="1773" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Transforming genes in chronic myelogenous leukemia</title>
		<author>
			<persName><forename type="first">E</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hjelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bishop</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="1952" to="1956" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>O'bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Frye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Cogswell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Neubauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Prokop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Espinosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Iii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Beau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Earp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="5016" to="5031" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A novel putative tyrosine kinase receptor with oncogenic potential</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Janssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Steenvoorden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmidberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Strehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ambros</forename><surname>Pf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bartram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="2113" to="2120" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>O'bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Fridell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Koski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varnum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="551" to="557" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Reichl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Starlinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Staufer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nenutil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Greplova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Valik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brostjan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="385" to="394" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hafizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dahlbäck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="295" to="304" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Expression of the proto-oncogene Axl in renal cell carcinoma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Malkowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Libertino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Mcgarvey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">DNA Cell Biol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="533" to="540" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and mer in the developing rat central nervous system</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Prieto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Comp Neurol</title>
		<imprint>
			<biblScope unit="volume">425</biblScope>
			<biblScope unit="page" from="295" to="314" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lafdil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Chobert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Couchie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brouillet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Zafrani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mavier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Laperche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="228" to="239" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The Gas6/Axl system: A novel regulator of vascular cell function</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Melaragno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Fridell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Berk</forename><surname>Bc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Cardiovasc Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="250" to="253" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Axl is essential for VEGF-A-dependent activation of PI3K/Akt</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">X</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kazlauskas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1692" to="1703" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Neubauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fiebeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>O'bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barckow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Serke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Siegert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Snodgrass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huhn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="1931" to="1941" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Angelillo-Scherrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>De Frutos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Aparicio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Melis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Savi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lupu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arnout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dewerchin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hoylaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Herbert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="215" to="221" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hanafusa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mizuno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">271</biblScope>
			<biblScope unit="page" from="30022" to="30027" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Genes specifically expressed at growth arrest of mammalian cells</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Philipson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="787" to="793" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Growth Arrest-specific gene 6 (gas6) and vascular hemostasis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Laurance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Lemarié</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Blostein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Nutr</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="196" to="203" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hafizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dahlbäck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS J</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="5231" to="5244" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Structural basis for Gas6-Axl signalling</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Knyazev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Clout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Cheburkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Göhring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Timpl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hohenester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="80" to="87" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">I</forename><surname>Tsou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Q</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Calarese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Garforth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Antes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Smirnov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Almo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Birge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Kotenko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">289</biblScope>
			<biblScope unit="page" from="25750" to="25763" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Sch lessi nger J a nd L em ke G: D i f ferent ia l TA M receptor-ligand-phospholipid interactions delimit differential TAM bioactivities</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Lew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Burrola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lax</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zagórska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Través</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Gertler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lauffenburger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Signal</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">66</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">AXL mediates resistance to cetuximab therapy</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Brand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Corrigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Braverman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Luthar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toulany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Gill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salgia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Kimple</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Wheeler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="5152" to="5164" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</title>
		<author>
			<persName><forename type="first">M</forename><surname>Elkabets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pazarentzos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Juric</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Pelossof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Brook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Benzaken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Morse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="533" to="546" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Fridell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Quilliam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burchert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mccloskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Spizz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varnum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Der</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="135" to="145" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site</title>
		<author>
			<persName><forename type="first">J</forename><surname>Braunger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schleithoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lammers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Bartram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Janssen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2619" to="2631" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Axl phosphorylates elmo scaffold proteins to promote Rac activation and cell invasion</title>
		<author>
			<persName><forename type="first">Abu-Thuraia</forename><surname>Gauthier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chidiac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fukui Screaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Côté</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="76" to="87" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Linger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Keating</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Earp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Ther Targets</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1073" to="1090" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Gas6 induces mesangial cell proliferation via latent transcription factor STAT3</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yanagita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ohashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mizuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fukatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">276</biblScope>
			<biblScope unit="page" from="42364" to="42369" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">TAM receptors in leukemia: Expression, signaling, and therapeutic implications</title>
		<author>
			<persName><forename type="first">L</forename><surname>Brandão</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Migdall-Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eisenman</forename><forename type="middle">K</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Oncog</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="47" to="63" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">R M</forename><surname>Linger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R A</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Cum M Ings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sat Her</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Migdall-Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Middleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Barón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Merrick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="3420" to="3431" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Iida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Niikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamada-Okabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sasano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1821" to="1827" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung</title>
		<author>
			<persName><forename type="first">T</forename><surname>Fujimori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Grabiec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kaur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fujino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Svedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Maciewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hussell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mucosal Immunol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1021" to="1030" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">K</forename><surname>Pang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Carrera</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Bosurgi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Miner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Diamond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Iwasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rothlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename></persName>
		</author>
		<idno>pii: e12414</idno>
	</analytic>
	<monogr>
		<title level="j">Elife</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Healy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Herrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varnum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Farber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Lung Cell Mol Physiol</title>
		<imprint>
			<biblScope unit="volume">280</biblScope>
			<biblScope unit="page" from="L1273" to="L1281" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename><forename type="middle">X</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">e1227</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma</title>
		<author>
			<persName><forename type="first">F</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wang</forename><forename type="middle">J</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Pathol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="6653" to="6661" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Epithelial-mesenchymal transitions in development and disease</title>
		<author>
			<persName><forename type="first">J P</forename><surname>Thier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Acloque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Nieto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="871" to="890" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs</title>
		<author>
			<persName><forename type="first">C</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mcnamara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Neve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Belmont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koeppen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Yauch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="5878" to="5890" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Byers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saintigny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Girard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peyton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Giri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Tumula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="279" to="290" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Hanahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Weinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The hallmarks of cancer. Cell</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="57" to="70" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sonobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nakayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kikuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kitamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Imamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Date</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="S467" to="S476" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Expression of axl in lung adenocarcinoma and correlation with tumor progression</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Shieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">R</forename><surname>Kao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Shiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lee</forename><surname>Hs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neoplasia</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1058" to="1064" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1935" to="1944" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kurokawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Omi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Goishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Higashiyama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="904" to="911" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcells expressing AXL</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Pao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Chuang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="3878" to="3887" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Oxidative stress enhances AXL-mediated cell migration through AKT1/Rac1-dependent mechanism</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Chuang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Free Radic Biol Med</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1246" to="1256" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Tai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Shieh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Shiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="4044" to="4055" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Reichl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dengler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Zijl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Führlinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reichel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sieghart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Peck-Radosavljevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grubinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mikulits</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="930" to="941" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Protumoral effect of macrophage through Axl activation on mucoepidermoid carcinoma</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Yuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Shieh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Oral Pathol Med</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="538" to="544" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Peng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">435</biblScope>
			<biblScope unit="page" from="493" to="500" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Asiedu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Beauchamp-Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ingle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Radisky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Knutson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1316" to="1324" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Puccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Hjelmeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Goidts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stem Cell Reports</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="899" to="913" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Novel mechanism for gonadotropin-releasing hormone neuronal migration involving Gas6/Ark signaling to p38 mitogen-activated protein kinase</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Linseman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Udo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Schaack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varnum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Kandel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Wierman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="599" to="613" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mahadevan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cooke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Swart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Simons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Croce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wisner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Iorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shakalya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Garewal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="3909" to="3919" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Kalinowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Candy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Epis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Goodall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Leedman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2541" to="2558" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL</title>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Greger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Greshock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Annan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Halsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Sathe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Gilmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="6871" to="6878" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Paccez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vogelsang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Zerbini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1024" to="1033" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Olivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Laframboise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abdel-Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="852" to="860" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Chun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">606</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Carstens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Scheible</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sugimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Lebleu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kalluri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">527</biblScope>
			<biblScope unit="page" from="525" to="530" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Durrans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>El Rayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Troeger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">527</biblScope>
			<biblScope unit="page" from="472" to="476" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varnum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hung</forename><surname>Mc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="329" to="336" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Papadakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cichoń</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Vyas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ghali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cerio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Storey</forename><forename type="middle">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O'toole</forename><surname>Ea</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="509" to="517" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Chuang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">268</biblScope>
			<biblScope unit="page" from="314" to="324" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">AM: Targeting the mTOR signaling network for cancer therapy</title>
		<author>
			<persName><forename type="first">F</forename><surname>Meric-Bernstam</surname></persName>
		</author>
		<author>
			<persName><surname>Gonzalez-Angulo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2278" to="2287" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor</title>
		<author>
			<persName><forename type="first">K</forename><surname>Suda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mizuuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takemoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Iwasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mitsudomi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1002" to="1006" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">AXL inhibitors in cancer: A medicinal chemistry perspective</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Brunton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Unciti-Broceta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="3593" to="3608" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Axl kinase as a key target for oncology: Focus on small molecule inhibitors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Feneyrolles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Spenlinhauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guiet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fauvel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Daydé-Cazals</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Warnault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chevé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yasri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Ther</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="2141" to="2148" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Axl receptor axis: A new therapeutic target in lung cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Brekken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Byers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Heymach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Gerber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1357" to="1362" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">AXL kinase as a novel target for cancer therapy</title>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Koul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Halmos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="9546" to="9563" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Holland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Franci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Torneros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Heckrodt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1544" to="1554" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">First Axl inhibitor enters clinical trials</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sheridan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotechnol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="775" to="776" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Imaging Axl expression in pancreatic and prostate cancer xenografts</title>
		<author>
			<persName><forename type="first">S</forename><surname>Nimmagadda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pullambhatla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lisok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maitra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Pomper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">443</biblScope>
			<biblScope unit="page" from="635" to="640" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">H</forename><surname>Qu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">W</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">I</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">G</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Lett</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1677" to="1685" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">AUY922 effectively overcomes MET-and AXL-mediated resistance to EGFR-TKI in lung cancer cells</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>So</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Baek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Bivona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">e0119832</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Park</forename><surname>Hj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="10146" to="10160" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Koomen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rawal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Fisher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="4059" to="4074" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1093" to="1102" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
